CSRxP Statement On Exclusion Of Big Pharma Accountability Amendment In Appropriations Bill
Sep 13, 2018
House Misses Bipartisan Opportunity To Hold Big Pharma Accountable… Read More
© 2026 CSRXP- All Rights Reserved
Statements
CSRxP Urges FDA To Finalize Guidance Critical To Lower Drug Prices
Aug 23, 2018
The Campaign for Sustainable Rx Pricing (CSRxP) today joined more than a dozen… Read More
CSRxP Applauds Trump Administration’s Focus on Out-of-Control Drug Prices
Aug 21, 2018
CSRxP spokesman Will Holley released the following statement applauding the… Read More
CSRxP Letter of Support for Durbin-Grassley DTC Advertising Amendment
Aug 21, 2018
Last night, Senators Durbin and Grassley filed an amendment to the Labor-HHS… Read More
CSRxP Statement on CMS Changes to Medicare Part B
Aug 7, 2018
CSRxP spokesman Will Holley released the following statement following… Read More
New Report Demonstrates Big Pharma’s Abuses of the Patent System
Aug 2, 2018
CSRxP spokesman Will Holley released the following statement on the release of… Read More
High Priced Drugs Lead to Banner Q2 Earnings for Big Pharma
Jul 27, 2018
CSRxP released the following statement following a week of strong Q2 earnings… Read More
CSRxP on Lilly & Biogen Earnings
Jul 24, 2018
CSRxP released the following statement following the release of Eli Lilly and… Read More
CSRxP Applauds Admin Focus on Drug Prices
Jul 19, 2018
CSRxP spokesman Will Holley released the following statement applauding the… Read More
CSRxP Applauds FDA’s Biosimilars Action Plan
Jul 18, 2018
“We applaud Commissioner Gottlieb and the FDA for their leadership on… Read More
CSRxP Releases Comments on Drug Price Blueprint
Jul 13, 2018
The Department of Health and Human Services is taking a good first step in the… Read More
CSRxP Statement on Novartis’ $475,000 Price Tag for Kymriah
Aug 30, 2017
"While we are very excited about the potential for CAR-T therapies to save lives, Novartis’ pricing decision disappointingly pushes an unsustainable trend even closer to the breaking point." Read More